Chronic graft versus host disease of oral mucosa: review of available therapies (Q36382986)

13 August 2017

1 reference

title

Chronic graft versus host disease of oral mucosa: review of available therapies (English)

1 reference

Chronic graft versus host disease

13 August 2017

0 references

2

Steven Z Pavletic

1 reference

13 August 2017

Matin M Imanguli

1

1 reference

13 August 2017

Jean-Pierre Guadagnini

series ordinal

3

1 reference

13 August 2017

Jaime S Brahim

series ordinal

4

1 reference

13 August 2017

Jane C Atkinson

series ordinal

5

1 reference

13 August 2017

1 February 2006

1 reference

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

13 August 2017

1 reference

13 August 2017

101

1 reference

13 August 2017

2

1 reference

13 August 2017

175-183

1 reference

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Hematopoietic stem cell transplantation in sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

New approaches for preventing and treating chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Chronic graft-versus-host disease: is there an alternative to the conventional treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Weight loss and malnutrition in patients with chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Oral manifestations of chronic graft-v-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

7 January 2021

Graft-vs.-host disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Use of cyclosporine in hematopoietic cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Sirolimus: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

7 January 2021

Mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Mechanism of action of extracorporeal photochemotherapy in chronic graft-versus-host disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Hydroxychloroquine for the treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Novel approaches to the treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Pentostatin for the treatment of chronic graft-versus-host disease in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Molecular action of methotrexate in inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

The use of methotrexate in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Successful treatment of chronic cutaneous graft-versus-host-disease (GVHD) with penicillamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Budesonide: a novel treatment for oral chronic graft versus host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Topical cyclosporin in the treatment of dermatologic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

CO2 laser in oral graft-versus-host disease: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Guidelines for prescribing azathioprine in dermatology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Response of oral lichen planus to topical tacrolimus in 37 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

Extracorporeal photochemotherapy for the treatment of graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2005.08.028

10.1016/J.TRIPLEO.2005.08.028

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference